


# Medicilon ADC R&D Service Platform



## Solutions

## Synthesis of ADC Payloads

.....

.....

.....

.....

- .....
  - .....
  - .....
- .....
- .....
- .....



.....

.....



### Medicilon Case:

ADC crosslinking strategy based on cysteine










### Medicilon Case:



### Medicilon Case:



### Medicilon Case:



## Pharmacology Research of ADC


- *In vivo* studies
- *In vitro* studies
- *In vivo* studies

## Pharmacology Evaluation of ADC

- *In vivo* studies
- *In vitro* studies
- *In vivo* studies

- *In vivo* studies
- *In vitro* studies
- *In vivo* studies
- *In vitro* studies
- *In vivo* studies
- *In vitro* studies
- *In vivo* studies
- *In vitro* studies

### Medicilon Case:



*In vivo*

*In vivo*  
Medicilon



## ADC Pharmacokinetics Study

.....

.....

.....

.....		
.....	Antibody with minimum of DAR 1	.....
.....	.....	.....
.....	.....	.....
.....	.....	.....



## ADC Immunogenicity

.....

.....

.....

## ADC Safety Assessment

.....

.....

- .....
- .....
- .....

## Medicilon Assisted Projects

### DAC-002

Medicilon completed preclinical pharmacokinetic and toxicological studies in this project, accelerating the development process.

### Muc1-ADC

Medicilon has provided a full set of preclinical research services including pharmacology, pharmacokinetics and safety evaluation in the research and development of new Muc1 drugs, helping the project to be successfully approved for clinical trials.

### BAT8006

ized anti-FR antibody and a toxic small molecule topoisomerase I inhibitor connected by a self-developed cleavable

During the R&D of BAT8006, Medicilon's ADC preclinical research and development service platform has extensive practical technology and experience in the field of ADC drug preclinical R&D, followed the ICH guidelines S6 and S9 and combined with the specific situation of the BAT8006 project, to customize a personalized safety evaluation plan and overcome the complexity and diversity of drug-to-antibody ratio (DAR), stability, for BAT8006.

### KM501

Medicilon, as a partner of Xuanzhu, provided KM501 with GLP-compliant preclinical research services based on the Medicilon Antibody Development Service Platform, including pharmacokinetic studies and safety evaluation.



**MEDICILON**

---

**Email:** ..... **Website:** ..... **Tel:** .....

**Global Headquarters:** .....

**US Laboratory:** .....